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Gastroesophageal reflux disease (GERD) is common. Manypatients with recurring or troublesome
symptoms are referredfor endoscopic examination. Patients seen in secondary care usually have
failed OTC or primary care anti-reflux therapy. Acid suppression is the mainstay ofhealing and
maintenance therapy. Increasingly proton pump inhibitors (PPIs) are preferred above H2 receptor
antagonists (H2RAs), not onlyfor the more severe end ofthe GERD spectrum but alsoforpatients
with mild degrees ofesophagitis. Not allpatients respond symptomatically to acid suppression, not
even with high dose PPI. Prokinetics are mainly useful in the milderdegrees ofGERD. It is still not
clear whether aparticular symptom cluster can be recognizedfor whichprokinetics are especially
useful. The concept of "step-up versus step-down" approach remains in needforproper validation.
Switchingfrom PPIs to cisapridefor "step-down" maintenance appears inadequate inpractice. All
current therapies have shortcomings; H2RAs insufficiently block meal-stimulated acid secretion;
long-term strong acid suppression worsens Helicobacter pylori-associated inflammation in the cor-
pus and may accelerate development ofatrophy; PPI-potency is substantially weaker in non-H.
pylori infected individuals. Optimization of individualized therapy will require more potent and
more precisely targeted motility modulating drugs and superior acid/peptic inhibiting pharmaceu-
ticals.
INTRODUCTION
This overview focuses on the current
medical possibilities and shortcomings to
heal and maintain remission in patients
with gastroesophageal reflux disease
(GERD)b in secondary and tertiary care
settings.
The clinical presentation of GERD
covers a wide spectrum of abnormalities,
including postprandial heartburn and acid
regurgitation. Recurrent or troublesome or
recalcitrant symptoms are the main reason
for specialist referral for endoscopic
examination. Indeed, physicians often use
endoscopic results to tailor medical thera-
py in patients with reflux symptomatology
[1].
GERD is in essence a motility disor-
der. Meticulous studies have shown that
transient relaxations of the lower
esophageal sphincter and of the crural
diaphragm are to be considered as the
dominant mechanism allowing reflux to
aTo whom all correspondence should be addressed: Prof. Dr. G.N.J.Tytgat, University of
Amsterdam, Academic Medical Center, Department of Gastroenterology & Hepatology,
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Tel.: 31-20-566-3634; Fax: 31-20-
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Figure 1. Healing rates: amalgamation of the literature.
occur especially in patients exhibiting the
milder end of the reflux spectrum [2]. So-
called spontaneous or stress-induced
reflux becomes more readily demonstra-
ble in patients with more severe GERD
and more severe impairment of sphincter
function. Particularly the studies of Mittal
[3, 4] have emphasized the double compo-
nent to the lower esophageal barriermech-
anism: the smooth muscle of the lower
esophageal sphincter proper and the striat-
ed muscle of the crural diaphragm.
Sphincteric function of the crural
diaphragm is particularly impaired in
patients with a hiatal hernia.
For many patients, GERD is a chron-
ic relapsing problem. This becomes readi-
ly apparent when confronted with the very
rapid and almost universal symptomatic
and/or endoscopic relapse after prior heal-
ing of reflux-induced damage with acid
suppressant drugs [5]. The main explana-
tion for this chronic relapsing nature is the
failure to correct the underlying motor
abnormality responsible for GERD. As no
medical therapy is capable of providing a
permanent correction of the motor disor-
der, it is logically to be expected that
reflux will recur as soon as therapy is
stopped.
PHARMACEUTICAL POSSIBILITIES
TO HEAL REFLUX ESOPHAGITIS
Traditionally, antireflux therapy starts
with general life style advice. To what
extent life style modifications (weight
reduction, avoiding of straining at stool,
avoiding gastric overdistension, etc.) can
control the reflux diathesis in the absence
of drug therapy is insufficiently known at
the present time. The widespread con-
sumption of drugs (OTC and prescription
drugs) would indicate that life-style
changes as sole therapeutic measure often
fail to control the disease.
There are essentially two pharmaco-
logical avenues, used in clinical practice,
to induce clinical and/or endoscopicTytgat: Medical therapy of GERD 221
remission in GERD. Prokinetics aim at
improving the motor abnormalities,
through increasing basal lower esophageal
sphincter pressure, improving peristaltic
quality and clearing efficacy and through
accelerating gastric emptying when
delayed [6]. Acid suppressants, be it H,-
receptor antagonists (H2RAs) or proton
pump inhibitors (PPIs), aim at decreasing
the volume and acidity of the refluxate
available for reflux [7, 8].
Amalgamation of the world literature
of drug efficacy to induce remission or
healing is schematically shown in Figure
1. As can be seen, PPIs are substantially
superior in inducing healing compared to
H2RAs and prokinetics. It should be
stressed that this difference in efficacy is
more marked in patients with more severe
mucosal damage. This difference is much
less clear for milder degrees of damage.
Many studies have shown that esophagitis
of greater severity is more difficult to heal
with H2RAs than lesser grades of
esophagitis. Based upon these data, it is
readily understandable that it is often said
that acid suppression is the best option for
initial therapy inpatients with troublesome
symptoms as this therapy is most likely to
succeed. Cost-effectiveness analyses also
suggest that PPIs are the best initial option
in patients with all degrees of esophagitis
as a prompt and predictable response to
reflux disease results in lower total utiliza-
tion of health care resources as well as a
reassured and comfortable patient.
The critical pH to be reached in
GERD is 4. Intraesophageal pH must be
maintained above 4 for at least 16 hr a day
and preferably longer to achieve mucosal
healing [9]. Meta-analysis has indeed
shown a correlation between acid suppres-
sion and healing of esophagitis, the heal-
ing proportion being directly related to the
degree and duration of acid suppression.
As a consequence PPIs show higher and
more effective healing compared to
H2RAs [10]. Meta-analysis predicts heal-
ing in approximately 90percent ofpatients
with erosive esophagitis within eight
weeks if intragastric acidity is maintained
above pH 4.0 for between 20 and 22 hours
per day [9]. Clinical differences between
the various PPIs (omeprazole, lansopra-
zole, pantoprazole), if any, may be
explained, at least in part, by differences in
oral bioavailability and the velocity to
reach the peak antisecretory effect [11].
Lanzoprazole seems to have an earlier
onset of action than omeprazole, ascribed
to higher bioavailability during the first
days oftreatment [12].
Numerous clinical trials have assessed
the healing rates at arbitrary time intervals.
Results ofhealing do not reflect a true rate
but rather represent the proportion of
patients healed. The speed at which heal-
ing occurs may be substantially different.
This healing rate can be determined by the
slope ofthehealing/time curve. The rate of
symptom relief can be determined in a
similar fashion. Calculation of speed of
healing and speed of symptoms relief has
been made by Chiba et al. [8]. PPIs show
a significantly faster healing rate (approx-
imately 12 percent/week) versus H2RAs
(approximately 6 percent/week) and pro-
vide faster and more complete heartburn
relief(approximately 12percent/week ver-
sus 6 percent/week). Thus healing and
symptom relief occur nearly twice as fast
with PPIs.
"STEP-UP"VERSUS "STEP-DOWN"
APPROACH?
Most patients with mild symptoms
can be successfully managed by lifestyle
modification plus antacids/alginates, sup-
plemented when necessary by courses of
H2RAs or prokinetics (cisapride). For
moderate to severe symptoms and for
moderate to severe esophagitis, PPIs are
increasingly favored as first line therapy.
Responses are also likely in patients who
have failed toimprove on H2RA treatment.
Yet the controversy regarding the
"step-up" and "step-down" approach con-
tinues. The "step-up" approach follows the
principle of applying the minimum phar-
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stated therapeutic objective. This approach
targets more powerful and costly therapy
towards patients with proven therapeutic
need for more intensive treatment. In con-
trast, in the "step-down" approach, the
patients are initially treated with the max-
imally effective (PPI) therapy, only being
"stepped-down" to less intensive interven-
tions in strictly defined circumstances. The
principal problem inherent in this
approach is the universal application of
powerful and costly drugs in patients in
whom less intensive interventions may
have been adequate but have not previous-
ly been proven to be ineffective.
PHARMACEUTICAL POSSIBILITIES
TO MAINTAIN REMISSION
Once healing is achieved and treat-
ment is stopped, recurrence is common,
particularly in patients with erosive
esophagitis. Maintenance therapy is, there-
fore, necessary in a large number of such
patients.
Amalgamation of the world literature
for remission rates during 12 months
maintenance therapy is schematically
shown in Figure 2. As can be seen, rough-
ly 60 percent of the patients can be main-
tained in remission with H2RAs and proki-
netics (cisapride). With PPIs, remission
can be maintained in roughly 90 percent.
These data are obtained when prokinetics
or acid suppressants are used in standard
dosage. Occasionally higher doses are
necessary to maintain remission [13-15].
A meta-analysis of long-term trials with
PPIs has shown that the latter are superior
to all other regimens with acid suppres-
sants in maintaining remission [16].
Carlsson et al. [16] conducted a
meta-analysis of long-term omeprazole
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Figure 2. Remission rates during maintenance therapy: amalgamation of the litera-
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Table 1. GERD: Complete symptom relief
Cisapride Ranitidine Omeprazole Lansoprazole Omeprazole Placebo
10 mg 15 mg 20 mg
Venables [26] 4w/994 40% 49% 61%
Galmiche [27] 4w/426 29% 42% 55%
Bardhan [28] 2w/448 26% 40% 55%
Jones[29] 4w/609 49% 60%
Lind [30] 4w/509 31% 46% 13%
trials in order to detect prognostic factors
influencing relapse of esophagitis. Data
from 1154 patients, included in five inde-
pendent randomized trials, were pooled
for this meta-analysis. Omeprazole 20
mg/d maintained 82 percent ofpatients in
endoscopic remission over a six-month
period compared to 72 percent for
omeprazole 10 mg, 52 percent for raniti-
dine 150 mg twice daily, and 11 percent
for placebo. Four factors were associated
with a higher relapse rate: pre-treatment
severity of esophagitis., young age, non-
smoking and moderate/severe regurgita-
tion before entry into the trials.
Permanent symptom relief was highly
predictive for maintenance of healing.
Patients over 65 years old were less like-
ly to relapse, probably due to decreased
metabolic clearance of omeprazole,
which would be expected to result in
greater bioavailability. The authors argue
that a low PPI dose should be the appro-
priate initial maintenance dose in the
elderly.
Subsequent management needs to
acknowledge that long-term therapy is
needed in most patients and that acid sup-
pression is one of the major options.
Available information suggests that ade-
quate symptom relief is possible provided
PPI dosage is adjusted upwards if the
response is incomplete. In patients who
respond completely to initial acid suppres-
sant therapy, this should be made as cost-
effective as possible by "step-down" ofthe
dose to the lowest cost option that controls
symptoms and esophagitis adequately.
Symptom control is a relatively sensitive
surrogate for adequate control of
esophagitis.
Very few data are available in the lit-
erature to support the value of the "step-
down" concept. Two recent studies looked
at the capability of maintaining remission
when switching to cisapride therapy after
prior healing with proton pump inhibitors
[17, 18]. In both studies, cisapride was no
better than placebo in maintaining the
remission. It remains puzzling why prior
healing with a PPI apparently jeopardizes
the efficacy of prokinetics, a phenomenon
that was already seen in the earlier large
scale "Scanedcis" study [19]. Whether the
same holds true for H2RAs is unknown at
the present time as no systematic studies
of "PPI-H2RA step-down" have been pub-
lished so far. Clinical experience teaches
thatit is difficult in practice to switch from
PPIs to H2RAs formaintenance. The alter-
native would be to decrease the dose ofthe
PPI. However several studies have now
shown that PPIs, at halfthe usual dose, are
inferior to full dose therapy in relieving
GERD symptomatology as summarized in
Table 1. The same is true for maintaining
endoscopic healing. Although, for exam-
ple, both 10 and 20 mg daily doses of
omeprazole can maintain remission, sig-
nificantly fewer patients maintained
remission after six months with the 10 mg
dose than with the 20 mg dosage (35 per-
cent versus 59 percent) [20].
Despite the above considerations,
clinical practice also teaches that many
patients gradually reduce the PPI dose and224 Tytgat: Medical therapy ofGERD
some are even able to stop those drugs and
continue only with antacids taken intermit-
tently forinstantaneous reliefofheartburn.
Proper guidelines on how to conduct long-
term acid suppressant therapy (dose? dura-
tion?) are lacking yet urgently needed. The
Practice Parameters Committee of the
American College ofGastroenterology has
published guidelines for the diagnosis and
treatment of gastroesophageal reflux dis-
ease [21]. The guidelines cite the PPIs as
the most effective medical therapy to con-
trol symptoms of GERD and heal
esophagitis and suggest that PPIs may be
used as initial therapy in some cases.
SHORTCOMINGS OF PHARMACO-
LOGICAL MAINTENANCETHERAPY
Effective control of the 24-hr
esophageal acid exposure is the most
effective medical therapy for healing and
maintenance in patients with reflux
esophagitis.
A major shortcoming of all trials in
reflux disease is the lack of specification
of the symptom patterns present in the
patients selected for the trials. GERD
symptomatology may vary substantially in
practice. Acid suppressants may well con-
trol heartburn but up to 20 percent of the
patients continue to complain ofregurgita-
tion, nocturnal cough and retrosternal
pain.
Prokinetics as monotherapy are main-
ly indicated for the milder end ofthe spec-
trum of reflux disease. Whether there are
patients with a specific symptom pattern
(e.g., associated dysmotility like dyspep-
sia?) who preferentially benefit from cis-
apride is unknown at the present time.
Combination of cisapride and acid sup-
pressants in patients with more intractable
disease has been insufficiently evaluated,
although notinfrequently done in practice.
PPIs are undoubtably superior to H2RAs
for symptom relief and endoscopic heal-
ing. H2RAs insufficiently suppress food
stimulated acid production. Moreover
tachyphylaxis and acidrebound is possible
[12, 22]. Boosting the H2RAs rarely pro-
duces the required effect. For more severe
reflux disease BID dosing of a proton
pump inhibitor is often necessary.
Occasionally acid rebound is also demon-
strable after stopping PPI therapy [23, 24].
FUTURE PROSPECTS
We have witnessed major progress in
medical, therapy of GERD over the last
few years, through the development of
more powerful prokinetics (cisapride) and
especially through the development of
PPIs for prolonged suppression of intra-
gastric acidity and intragastric volume
available for reflux. Yet the optimal goals
have still not been reached and areas of
improvement can be envisaged. The basic
disturbances causing transient sphincter
relaxation need further unraveling. Some
very recent studies would indicate that it
may well bepossible to interfere with tran-
sient relaxations, for example through
antagonism of the cholecystokinin A
receptor [25]. Other modalities to regulate
sphincter function are currently being
explored.
Long-term modulation of intragastric
acidity may also improve through further
refinement of blockade of the acid pumps
or through combination therapy. Also fur-
ther improvement of surgical possibilities
is to be expected, in parallel with the phar-
macological improvement. Whether
simultaneous prevention of intestinal
metaplasia in the cardia or in the distal
esophagus in patients with GERD is a
reachable aim with pharmacological or
surgical therapy will require carefully con-
ducted long-term evaluations.
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